| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Gil Zalsman, Einat Carmon, Andrés Martin, Daniela Bensason, Abraham Weizman, Samuel Tyan. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. Journal of child and adolescent psychopharmacology. vol 13. issue 3. 2003-12-19. PMID:14642020. |
effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. |
2003-12-19 |
2023-08-12 |
human |
| Gil Zalsman, Einat Carmon, Andrés Martin, Daniela Bensason, Abraham Weizman, Samuel Tyan. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. Journal of child and adolescent psychopharmacology. vol 13. issue 3. 2003-12-19. PMID:14642020. |
data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce. |
2003-12-19 |
2023-08-12 |
human |
| Gil Zalsman, Einat Carmon, Andrés Martin, Daniela Bensason, Abraham Weizman, Samuel Tyan. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. Journal of child and adolescent psychopharmacology. vol 13. issue 3. 2003-12-19. PMID:14642020. |
the aim of this open-label, prospective study was to estimate the effectiveness, safety, and tolerability of risperidone treatment in adolescents with first-episode schizophrenia. |
2003-12-19 |
2023-08-12 |
human |
| Gil Zalsman, Einat Carmon, Andrés Martin, Daniela Bensason, Abraham Weizman, Samuel Tyan. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. Journal of child and adolescent psychopharmacology. vol 13. issue 3. 2003-12-19. PMID:14642020. |
in conclusion risperidone appears to be a safe, acceptably tolerated, and effective antipsychotic medication for the treatment of adolescent-onset schizophrenia. |
2003-12-19 |
2023-08-12 |
human |
| Matthew J Byerly, Mary Weber, Deean Brooks, Sara Beth Casey, Sheila Elliot, Jason Hawkin. Cost evaluation of risperidone compared with olanzapine. Psychiatric services (Washington, D.C.). vol 54. issue 5. 2003-12-12. PMID:12719509. |
this study evaluated costs associated with risperidone and olanzapine treatment for schizophrenia. |
2003-12-12 |
2023-08-12 |
Not clear |
| Oye Gureje, Wayne Miles, Nicholas Keks, David Grainger, Timothy Lambert, John McGrath, Pierre Tran, Stanley Catts, Allen Fraser, Harry Hustig, Scott Andersen, Ann Marie Crawfor. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729882. |
olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in australia and new zealand. |
2003-12-09 |
2023-08-12 |
Not clear |
| Kazuo Mihara, Tsuyoshi Kondo, Norio Yasui-Furukori, Akihito Suzuki, Masayuki Ishida, Shingo Ono, Takahiro Kubota, Tatsuji Iga, Yutaka Takarada, Ronald de Vries, Sunao Kanek. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Therapeutic drug monitoring. vol 25. issue 3. 2003-12-09. PMID:12766554. |
effects of various cyp2d6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in japanese patients with schizophrenia. |
2003-12-09 |
2023-08-12 |
Not clear |
| Stephen D Martin, Susan E Libretto, David J Pratt, J S Brewin, Zahid-Ul Huq, B T Sale. Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone. Current medical research and opinion. vol 19. issue 4. 2003-12-03. PMID:12841922. |
to detail specific effects of long-acting risperidone on individuals with schizophrenia and their way of life in a series of four cases. |
2003-12-03 |
2023-08-12 |
Not clear |
| M Mazza, C Tozzini, P Giosué, A De Risio, M Palmucci, R Roncone, M Casacchi. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study]. La Clinica terapeutica. vol 154. issue 2. 2003-11-24. PMID:12856365. |
our study was conducted in the form of naturalistic observation of a sample of 45 people affected by schizophrenia treated with haloperidol, clozapine and risperidone. |
2003-11-24 |
2023-08-12 |
Not clear |
| Philip D Harvey, Judy A Napolitano, Lian Mao, Georges Gharabaw. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. International journal of geriatric psychiatry. vol 18. issue 9. 2003-11-12. PMID:12949850. |
comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. |
2003-11-12 |
2023-08-12 |
Not clear |
| Philip D Harvey, Judy A Napolitano, Lian Mao, Georges Gharabaw. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. International journal of geriatric psychiatry. vol 18. issue 9. 2003-11-12. PMID:12949850. |
to examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder. |
2003-11-12 |
2023-08-12 |
Not clear |
| Vasilis P Bozikas, Charoula Deseri, Stergios Pitsavas, Athanasios Karavato. Antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 48. issue 6. 2003-10-21. PMID:12894620. |
antiaggressive action of combined risperidone and quetiapine in a patient with schizophrenia. |
2003-10-21 |
2023-08-12 |
Not clear |
| Jeanette M Jerrel. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophrenia bulletin. vol 28. issue 4. 2003-10-15. PMID:12795493. |
to assess the cost and effectiveness of risperidone, olanzapine, and conventional antipsychotic medications under "usual practice" conditions in a large, public mental health system, 108 persons diagnosed with schizophrenia or schizoaffective disorder were randomly assigned to one of these three medication groups and followed prospectively over a 12-month period using standard instruments and procedures. |
2003-10-15 |
2023-08-12 |
human |
| Jelena Barkić, Pavo Filaković, Ljiljana Radanović-Grgurić, Oliver Koić, Davor Laufer, Ivan Pozgain, Elvira Koić, Ljubomir Hotuja. The influence of risperidone on cognitive functions in schizophrenia. Collegium antropologicum. vol 27 Suppl 1. 2003-10-09. PMID:12955900. |
the influence of risperidone on cognitive functions in schizophrenia. |
2003-10-09 |
2023-08-12 |
human |
| Masahisa Sannomiya, Hisatoshi Katsu, Kazuhiko Nakayam. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 105. issue 5. 2003-10-02. PMID:12875232. |
[a clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. |
2003-10-02 |
2023-08-12 |
Not clear |
| Masahisa Sannomiya, Hisatoshi Katsu, Kazuhiko Nakayam. [A clinical study of emergent anxiety in neuroleptic-naïve, first-episode schizophrenia patients following treatment with risperidone]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica. vol 105. issue 5. 2003-10-02. PMID:12875232. |
risperidone (ris) alone was administered to patients with neuroleptic-naïve, first-episode schizophrenia who visited the outpatient clinic of the department of psychiatry, jikei university school of medicine hospital between april 1998 and december 2001, and the effectiveness of the drug in alleviating anxiety symptoms was prospectively examined. |
2003-10-02 |
2023-08-12 |
Not clear |
| Won-Myong Bahk, Chi-Un Pae, Jeong-Ho Chae, Kwang-Soo Kim, Tae-Youn Jun, Joshua Tsoh, Dai-Jin Kim, Chung-Tai Lee, Chul Lee, Sang-Ick Han, Bo-Moon Choi, Jin-Hee Han, Hyo-Jin G. A naturalistic study of risperidone treatment in seven affiliated university hospitals in Korea. Psychiatry and clinical neurosciences. vol 57. issue 1. 2003-09-30. PMID:12519459. |
data on 210 of 580 inpatients with schizophrenia who were treated with risperidone and whose complete medical records were available, were analyzed. |
2003-09-30 |
2023-08-12 |
human |
| Christopher D Carlson, Patrizia A Cavazzoni, Paul H Berg, Hank Wei, Charles M Beasley, John M Kan. An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. The Journal of clinical psychiatry. vol 64. issue 8. 2003-09-25. PMID:12927004. |
an integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine. |
2003-09-25 |
2023-08-12 |
Not clear |
| Karen L Rascati, Michael T Johnsrud, M Lynn Crismon, Maureen J Lage, Beth L Barbe. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. PharmacoEconomics. vol 21. issue 10. 2003-09-24. PMID:12828491. |
olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among texas medicaid recipients. |
2003-09-24 |
2023-08-12 |
Not clear |
| Karen L Rascati, Michael T Johnsrud, M Lynn Crismon, Maureen J Lage, Beth L Barbe. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. PharmacoEconomics. vol 21. issue 10. 2003-09-24. PMID:12828491. |
to examine both schizophrenia-related costs and total (schizophrenia plus non-schizophrenia) healthcare costs among texas medicaid recipients who had been diagnosed with a schizophrenic disorder and had been initiated on olanzapine or risperidone. |
2003-09-24 |
2023-08-12 |
Not clear |